Shares in Amplitude Energy Ltd (ASX: AEL) have fallen more than 40% over the past 12 months, but if the analysts at Macquarie are to be believed, they are in line for a re-rating.

The broker has published a new research note on the gas producer with a bullish share price target which I’ll get to shortly.

First, let’s have a look at Amplitude’s recent full-year results release.

Solid operating results from Amplitude

The Otway Basin-focussed company delivered record full-year production of 27.6 petajoules of gas, up 3% on the previous year.

Revenue meanwhile was up 7% to $285.8 million, and underlying earnings were a record $191.8 million, up 12%.  

Managing Director Jane Norman said the company was delivering on its strategy.

She added:

Amplitude Energy has delivered record financial results for the third consecutive year, underpinned by solid operational performance and continued cash flow improvement through FY26. The business remains resilient in the face of external challenges. With strong base business cash flows providing funding for our growth projects, the Company is well placed to maximise its long-term value. Record production performance was driven by Orbost, where production was increased above the plant’s previous 68 TJ/day nameplate level. Orbost has since demonstrated an ability to operate well above 70 TJ/day, recently setting a series of new production records.

Ms Norman said the company was on track to achieve “transformational growth through the East Coast Supply Project, one of the most significant sources of new domestic gas supply currently being advanced in south-east Australia”.

She added:

Our acquisition of the discovered Artisan gas field, combined with our existing Annie discovery, provides the basis for a very attractive project, with further potential near-term exploration upside from Juliet drilling. The Artisan transaction is a good example of cooperation between Otway Basin participants leading to project synergies, and was made possible in part by our strong relationship with O.G. Energy.

Amplitude is forecasting production of 26.6-28.5 petajoules of gas in FY27.

Amplitude Energy shares looking cheap

Macquarie said in its research note that 80% of Amplitude’s legacy gas was contracted for the current calendar year, along with 80% of Annie and Artisan.

Macquarie added:

Recent contracts with AGL & Energy Australia have been well timed, and reflect the prudent approach of steadily engaging high quality, well capitalised customers over time and de-risking the project. AEL now has an impressive track record of operational delivery (not the case in exploration, however this could change very soon with Juliet), and production guidance was in line with our expectations.

Macquarie has a price target of $2.45 for Amplitude Energy shares, compared with the current price of $1.62.

The post Macquarie tips this ASX gas company to jump more than 50% appeared first on The Motley Fool Australia.

More reading

• These 3 ASX 200 shares look like classic Warren Buffett investments
• 20% a year: Is this the ASX’s best index fund?
• CSL shares rebound 79% from multi-year low: Here’s what brokers tip next
• Buy $5,000 of Cochlear shares today and it could be worth this much in 12 months
• Why Evolution Mining, Whitehaven and Santos shares are creating a buzz on Wednesday

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares are climbing higher again today.

At the time of writing, the ASX biotech shares are up another 5%, and are changing hands for $165.76 a piece.

Today’s increase follows a huge 17% share price rally on Tuesday after CSL posted its FY26 results. The day goes down in history as the shares best day in 20 years.

CSL reported total revenue of US$15.8 billion and NPAT of US$2.6 billion. It also recorded a net loss after tax of US$2.6 billion for FY26, coming from pre-tax impairments and restructuring costs. 

The result came in way ahead of guidance. In May, the company cut its FY26 revenue guidance to around US$15.2 billion and NPAT to around US$3.1 billion. IT also flagged US$5 billion of impairments.

CSL management describes FY26 as a ‘reset year’, with FY27 marking a return to growth.

Clearly investors are thrilled with the update, and many are rushing to snap up the shares while they’re still trading for cheap.

CSL shares have now rebounded 79% from a multi-year low of $92.24 each in early-June. They’re now just 4% lower for the year-to-date, but still around 27% lower than 12 months ago.

Can they keep climbing higher?

Here’s what the experts think.

What’s the outlook for CSL shares over the next 12 months?

I think there is a lot of potential for the company to grow over the next few years. CSL is operating in a high-growth market, and its blood plasma division dominates the market for rare blood disorders and immunoglobulin products.

The company’s growth initiatives are clearly working, but it’s likely it will take a while longer to see the financial benefits.

I think we’ll see an upside ahead, but I don’t think we’ll see a material increase in the share price from here until we get more visibility into the company’s earnings over the first half of FY27.

It’s possible that some experts could revise their outlook on CSL shares in the coming days, off the back of the company’s results announcement.

But at the moment, forecasts suggest that they’re on the fence.

Market Index data shows that the majority have a hold rating on CSL shares. The $132 average target price now implies a potential 20% downside, after this week’s share price rally.

It’s the same case on TradingView. The majority (10 out of 17) have a hold rating on the stock. However, the other seven rate CSL shares as a buy/strong buy.

The average $160.28 target price is higher, but it still implies a potential downside of around 3%, at the time of writing.

However the range between the maximum and minimum target price is quite large. Some tip the shares to climb another 26% to $206.91 but others think CSL shares could drop 35% to just $106.80 over the next 12 months.

The post CSL shares rebound 79% from multi-year low: Here’s what brokers tip next appeared first on The Motley Fool Australia.

More reading

• CSL shares just had their best day in 20 years. What did I just miss?
• Is the CSL share price in the buy zone after the biotech giant’s results?
• 5 things to watch on the ASX 200 on Wednesday
• Here are the top 10 ASX 200 shares today
• CSL shares surge 18% as ‘reset year’ points to a return to growth

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Cochlear Ltd (ASX: COH) shares are up around 1% and changing hands at $141.96 a piece, at the time of writing on Wednesday morning.

The latest increase comes off the back of a 8% share price hike on Tuesday, following the company’s latest FY26 results announcement.

Cochlear posted a 2% increase in sales revenue and a 22% decrease in its underlying net profit, which came in right at the top end of guidance.

There were some significant positives though. Cochlear’s operating cash flow surged $130 million to $368 million, while free cash flow also improved substantially. The company also continued to invest aggressively in research and development, lifting R&D spending 15% as it accelerated work on its product pipeline.

Clearly investors were pleased with the results and its shares have kept climbing higher.

It’s great news for the stock after Cochlear shares suffered a huge 41% one-day crash in late-April after the company downgraded its guidance figures. 

Since hitting a 10-year low of just $90 cents per share in late-April, Cochlear shares have now rebounded 52%. There is still a long way to go, however. The shares are now down around 46% for the year-to-date and are roughly 52% lower than this time last year.

The question now is, can Cochlear shares keep climbing higher?

What do analysts tip next for Cochlear shares?

It’s possible that brokers and analysts could revise their stance on Cochlear shares in coming days, following the company’s FY26 update yesterday.

But at the time of writing, it looks like the experts are still on the fence about the outlook for the hearing implant company’s shares over the next 12 months.

Many are now uncertain that Cochlear shares can stage a meaningful recovery over the next 12 months. And some believe the shares are now above fair value.

Market Index data shows the majority of brokers have a hold rating on Cochlear shares. The $116.08 average target price now implies a potential 18% downside from the current trading price, at the time of writing.

TradingView data shows something similar, although the figures are a little less pessimistic. Again, the majority of analysts have a hold rating on the shares. The $139.21 average target price implies a potential 2% downside over the next 12 months, at the time of writing.

So, if I invest $5,000 into Cochlear shares today, what could it be worth in 12 months?

These forecasts suggest that a $5,000 investment into Cochlear shares today, could fall to somewhere around $4,100 to $4,900 by this time next year. That implies a loss of up to $900.

What could drive Cochlear shares higher?

It’s been a difficult year for the medical hearing implant device company. Cochlear has suffered from a number of strong headwinds, including a sector-wide rotation away from ASX healthcare shares this year. 

Looking ahead, I still see Cochlear as a strong, globally dominant business with its long-term outlook intact. I think the steep sell-offs this year were overdone and that the share price could quietly keep climbing higher.

The post Buy $5,000 of Cochlear shares today and it could be worth this much in 12 months appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Why are Cochlear shares flying 7% higher today?
• Cochlear posts FY26 profit at top end of guidance with new product momentum
• Down 50% – Are these the best value ASX 200 shares right now?
• Reporting season half-time report: 5 lessons from August so far

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.